Andrew Loblaw, MD, FRCPC, MSc, clinician scientist, radiation oncologist, Sunnybrook Health Sciences Centre, discusses a study that looked at using active surveillance to monitor men with intermediate-risk prostate cancer.

This study analyzed approximately 950 men with low- or intermediate-risk disease. Patients were monitored using physical examinations, biopsies, and blood tests and were analyzed for the impact on overall survival, cost-specific survival, time to treatment, and PSA control.

In this study, the risk of dying from prostate cancer increased significantly when active surveillance was used in men with intermediate-risk disease compared with their low-risk counterparts.

View more from the 2015 GU Cancer Symposium

Andrew Loblaw, MD, FRCPC, MSc

Articles

Dr. Loblaw on Monitoring Men With Intermediate-Risk Prostate Cancer